Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Robert Puckrin, Colin Stewart, Carolyn Owen, Lesley E. Street, Sarah Perry, Peter Duggan, Mona Shafey, Neil Chua, Douglas A. Stewart

Blood (2023) 142 (Supplement 1): 3595.

https://doi.org/10.1182/blood-2023-178085

Published: 2023

Journal Articles

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Douglas A. Stewart, Robert Puckrin

Blood (2023) 142 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2023-178097

Published: 2023

Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla

Blood (2022) 140 (Supplement 1): 3734–3736.

https://doi.org/10.1182/blood-2022-163706

Published: 2022

Journal Articles

External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

Carolyn Owen, Neil Chua, Devon Boyne, Ofodile Joe-Uzuegbu, Huma Shakir, Priyanka Gonga, Darren Brenner, Julia Elia-Pacitti, Emmanuel Ewara, Winson Y Cheung

Blood (2022) 140 (Supplement 1): 8024–8025.

https://doi.org/10.1182/blood-2022-160340

Published: 2022

Journal Articles

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

Robert Puckrin, Russell Sterrett, Neil Chua, Carolyn Owen, Peter Duggan, Mona Shafey, Douglas A. Stewart

Blood (2022) 140 (Supplement 1): 10581–10582.

https://doi.org/10.1182/blood-2022-162850

Published: 2022

Journal Articles

Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience

Farheen Manji, Eric Chow, Alina S. Gerrie, Neil Chua, Robert Puckrin, Douglas A. Stewart, Pamela Skrabek, Isabelle Bence-Bruckler, Mary-Margaret Keating, Joanne Britto, Gwynivere A Davies, Vishal Kukreti, John Kuruvilla, Michael Crump

Blood (2021) 138 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2021-146036

Published: 2021

Journal Articles

Favorable Outcomes with Thiotepa/Busulfan-Based Conditioning and Autotransplant for Patients with Aggressive B-Cell Lymphoma and Secondary CNS Involvement

Robert Puckrin, Neil Chua, Mona Shafey, Douglas A. Stewart

Blood (2021) 138 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2021-146103

Published: 2021

Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, MDMPH, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, MD, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle-Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, Denis Sahin, Umberto Vitolo, MD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 824.

https://doi.org/10.1182/blood.V130.Suppl_1.824.824

Published: 2017

Journal Articles

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Blood (2016) 128 (22): 470.

https://doi.org/10.1182/blood.V128.22.470.470

Published: 2016

Journal Articles

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Joanna Graczyk, MD FRCPC, Sunita Ghosh, PhD, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC, Carolyn J. Owen, MD FRCPC

Blood (2014) 124 (21): 2520.

https://doi.org/10.1182/blood.V124.21.2520.2520

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Danielle H. Oh, MB ChB, Qiuli Duan, MSc, Anthea Peters, MD MSc, FRCPC, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2014) 124 (21): 3972.

https://doi.org/10.1182/blood.V124.21.3972.3972

Published: 2014

Journal Articles

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 5078.

https://doi.org/10.1182/blood.V122.21.5078.5078

Published: 2013

Journal Articles

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Ethan Toumishey, B. Sc, Angeli Prasad, CCRP, Gregory S. Dueck, MD, MSc, BSc, FRCPC, Neil Chua, MD, FRCPC, Daygen Finch, MD, Douglas A. Stewart, MD, FRCPC, Darrell J. White, MD, Richard H. van der Jagt, MD, FRCPC, James B Johnston, MD, Andrew R Belch, MD, Tony Reiman, MD

Blood (2013) 122 (21): 4376.

https://doi.org/10.1182/blood.V122.21.4376.4376

Published: 2013

Journal Articles

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, FRCPC, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 3023.

https://doi.org/10.1182/blood.V122.21.3023.3023

Published: 2013

Journal Articles

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Carolyn J Owen, MD, FRCPC, Andrew Daly, MD, FRCPC, Neil Chua, MD, FRCPC, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 1346.

https://doi.org/10.1182/blood.V116.21.1346.1346

Published: 2010

Journal Articles

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Rena Buckstein, MD, John Kuruvilla, MD, Neil Chua, MD, Christina Lee, David A Macdonald, MD, Abdulwahab J. Al-Tourah, MD, Alison Foo, Wendy Walsh, S. Percy Ivy, MD, Michael Crump, MD, Elizabeth Eisenhauer, MD

Blood (2009) 114 (22): 2729.

https://doi.org/10.1182/blood.V114.22.2729.2729

Published: 2009

Journal Articles

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Tony Reiman, MD, Daygen Finch, MD, Neil Chua, MD, Darrell White, MD, Douglas A. Stewart, MD, Richard van der Jagt, MD, James Johnston, MD, Angeli Prasad, Henry Schwarz, Jerome Zeldis, MD, Andrew R. Belch, MD

Blood (2007) 110 (11): 2579.

https://doi.org/10.1182/blood.V110.11.2579.2579

Published: 2007

NARROW

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience

Favorable Outcomes with Thiotepa/Busulfan-Based Conditioning and Autotransplant for Patients with Aggressive B-Cell Lymphoma and Secondary CNS Involvement

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only